The FDA approved an intravenous (IV) formulation of fosfomycin (Contepo) to treat adults with complicated urinary tract ...
The U.S. Food and Drug Administration has approved elinzanetant, a new non-hormonal treatment to help women manage menopause ...
UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...
Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...
In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...
MedPage Today on MSN
Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug
T he FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...
The U.S. Food and Drug Administration has approved Lynkuet, a new medication that does not contain hormones to treat hot ...
The FDA has approved the Tendyne device to replace the mitral heart valve through a small incision between the ribs. Dr. Paul ...
A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.
FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.
GlobalData on MSN
FDA approves UCB’s Kygevvi for genetic mitochondrial disease
The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme.
Elinzanetant belongs to a new class of drugs designed to target what is believed to be a key mechanism responsible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback